There was a significant interaction between APOE and baseline statin therapy in relation to CHD composite and total CVD events, whereby APOE4+ carriers using statins had significantly lower risk (ps for interactions = 0.03) compared with APOE3 carriers not using statins (Supplementary Figure 1). The gene discussed is APOE; the disease is coronary artery disorder.